Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

Olsson, H. LU orcid ; Borg, Å LU ; Ewers, S. B. LU ; Fernö, M. LU ; Möller, T. LU and Ranstam, J. (1986) In Medical Oncology and Tumor Pharmacotherapy 3(2). p.77-81
Abstract

In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P<0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=-0.17;P<0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings. The ratio of plasma prolactin and estrogen receptor was significantly greater (P<0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size... (More)

In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P<0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=-0.17;P<0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings. The ratio of plasma prolactin and estrogen receptor was significantly greater (P<0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size was significantly greater in the group of early users (P<0.003). The findings indicate that breast tumours developing in previous early users of oral contraceptives have a low estrogen receptor concentration, while these patients have plasma prolactin. The tumour size is greater in early users indicating a poorer prognosis than other women with breast cancer. As early use of oral contraceptives increases, breast cancer risk and a high ratio of plasma prolactin and estrogen receptor concentration of the primary tumour characterize early oral contraceptive users the ratio may be a valuable marker for the breast cancer risk.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Estrogen receptor, Marker, Oral contraceptive use, Plasma prolactin, Premenopausal breast cancer, Progesterone receptor
in
Medical Oncology and Tumor Pharmacotherapy
volume
3
issue
2
pages
77 - 81
publisher
Humana Press
external identifiers
  • pmid:3747639
  • scopus:0022454766
ISSN
0736-0118
language
English
LU publication?
yes
id
9609148a-0516-47d7-897a-543050cdfdfb
alternative location
https://link.springer.com/article/10.1007/BF02934557
date added to LUP
2018-12-17 15:08:10
date last changed
2024-01-15 10:03:19
@article{9609148a-0516-47d7-897a-543050cdfdfb,
  abstract     = {{<p>In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P&lt;0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=-0.17;P&lt;0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings. The ratio of plasma prolactin and estrogen receptor was significantly greater (P&lt;0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size was significantly greater in the group of early users (P&lt;0.003). The findings indicate that breast tumours developing in previous early users of oral contraceptives have a low estrogen receptor concentration, while these patients have plasma prolactin. The tumour size is greater in early users indicating a poorer prognosis than other women with breast cancer. As early use of oral contraceptives increases, breast cancer risk and a high ratio of plasma prolactin and estrogen receptor concentration of the primary tumour characterize early oral contraceptive users the ratio may be a valuable marker for the breast cancer risk.</p>}},
  author       = {{Olsson, H. and Borg, Å and Ewers, S. B. and Fernö, M. and Möller, T. and Ranstam, J.}},
  issn         = {{0736-0118}},
  keywords     = {{Estrogen receptor; Marker; Oral contraceptive use; Plasma prolactin; Premenopausal breast cancer; Progesterone receptor}},
  language     = {{eng}},
  month        = {{06}},
  number       = {{2}},
  pages        = {{77--81}},
  publisher    = {{Humana Press}},
  series       = {{Medical Oncology and Tumor Pharmacotherapy}},
  title        = {{A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer}},
  url          = {{https://link.springer.com/article/10.1007/BF02934557}},
  volume       = {{3}},
  year         = {{1986}},
}